Immunic, Inc. (IMUX): Price and Financial Metrics
IMUX Price/Volume Stats
Current price | $1.30 | 52-week high | $3.11 |
Prev. close | $1.28 | 52-week low | $0.95 |
Day low | $1.26 | Volume | 170,600 |
Day high | $1.32 | Avg. volume | 1,031,352 |
50-day MA | $1.29 | Dividend yield | N/A |
200-day MA | $1.50 | Market Cap | 116.91M |
IMUX Stock Price Chart Interactive Chart >
Immunic, Inc. (IMUX) Company Bio
Immunic Inc. (formerly Vital Therapies) is a biotherapeutic company developing a cell-based therapy targeting the treatment of liver failure. The company was founded in 2003 and is based in San Diego, California.
Latest IMUX News From Around the Web
Below are the latest news stories about IMMUNIC INC that investors may wish to consider to help them evaluate IMUX as an investment opportunity.
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple SclerosisImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/992,162, entitled, "Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases." |
Immunic focusing on business development during Q4Immunic Inc President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a third-quarter update. |
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update. |
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate UpdateImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2023, including a corporate update, on Tuesday, November 14, 2023, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. |
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its SaltsImmunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/391,442, entitled, "Treatment of Multiple Sclerosis Comprising DHODH Inhibitors," covering a daily dose of about 10 mg to 45 mg of vidofludimus calcium (IMU-838) and other |
IMUX Price Returns
1-mo | -6.47% |
3-mo | -13.33% |
6-mo | -11.56% |
1-year | -12.16% |
3-year | -90.85% |
5-year | -83.51% |
YTD | -13.33% |
2023 | 7.14% |
2022 | -85.37% |
2021 | -37.41% |
2020 | 57.63% |
2019 | 27.63% |
Loading social stream, please wait...